Topic Highlight
Copyright ©2014 Baishideng Publishing Group Co.
World J Gastroenterol. Apr 14, 2014; 20(14): 3858-3874
Published online Apr 14, 2014. doi: 10.3748/wjg.v20.i14.3858
Table 1 Predictive and prognostic biomarkers for biological therapy in metastatic colorectal cancer
BiomarkerPrevalenceEvidence availablePredictive and prognostic value
KRAS mutations40%ConclusiveNegative predictive biomarker for anti-EGFR mAbs
InsufficientPredicts poor prognosis, but not an independent prognostic factor
BRAF mutations10%SubstantialPrognostic marker for poor outcome
InsufficientPotential predictive marker for resistance to anti-EGFR mAbs
NRAS mutations3%-5%Insufficient1Potential predictive marker for resistance to anti-EGFR mAbs
PIK3CA mutations15%-20%Insufficient1Potential predictive marker for resistance to cetuximab (exon 20, not exon 9 mutations)
Potential prognostic marker for poor outcome
PTEN (loss of expression)20%-40%Insufficient1Potential predictive marker for resistance to cetuximab
Associated with activation of the PIK3CA pathway and adverse disease outcome
P53 mutations1%-5%Insufficient1An independent predictive factor for cetuximab benefit
Not prognostic
Epiregulin, amphiregulin (high expression)50%-60%Insufficient1Associated with resistance to anti-EGFR antibody therapy and adverse clinical outcome
VEGF-D40%-75%Insufficient1Potential predictive marker for response to bevacizumab
VEGF-AInsufficient1Not predictive of response to bevacizumab
Table 2 Summary of key biomarkers investigated in clinical trials of bevacizumab
Key biomarkers evaluated
KRAS mutational status
BRAF mutational status
p53 mutational status
VEGF and VEGFR-2 (KDR) gene expression
VEGF A- to VEGF-D, VEGFR-1, and VEGFR-2 protein expression
CD31 expression
Neuropilin expression
Stromal thrombospondin-2 expression
Microvessel density
Plasma VEGF levels